Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

PARIS & MONTREAL--(BUSINESS WIRE)--

Regulatory News:

Ipsen (IPN.PA) (Euronext: IPN, ADR: IPSEY) today announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013.

Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsens group, stated: This presentation is in line with Ipsens commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysportwill now be available in Canada for the treatment of glabellar lines.

About Dysport

The active substance in Dysport is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of muscular spasticity, including cervical dystonia (or spasmodic torticollis, a chronic condition in which the neck is twisted or deviated), spasticity of the upper/lower part of the body in adults after a stroke, dynamic equinus foot deformity in children with cerebral palsy, blepharospasm (involuntary contraction of the eyelids) and hemifacial spasm (involuntary contraction of the muscles located on one side of the face). Dysport was later developed for the treatment of a wide variety of neuromuscular disorders, as well as for use in aesthetic medicine. On 31 December 2012, Dysport had marketing authorizations in force in 75 countries. In Canada, Dysport has been approved for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age since June 12th, 2012.

About the agreement with Valeant

In March 2006, the Ipsen Group signed an agreement with the Medicis Group (USA) granting the latter the exclusive right to develop, sell and market certain formulations of botulinum toxin type A for use in aesthetic medicine indications approved in the United States and Canada. On December 11th, 2012, Medicis was acquired by Valeant, who has succeeded Medicis in its rights of Dysport in North America.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding 1.2 billion in 2012. Ipsens ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships.Ipsen'sR&D is focused onitsinnovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to 250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsens shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the Service de Rglement Diffr (SRD). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visitwww.ipsen.com.

Read more:

Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada